Please login to the form below

Not currently logged in
Email:
Password:

The Medicines Company appoints Biogen's Tony Kingsley

He will be the New Jersey firm's president and COO

The Medicines Company Tony KingsleyBiogen's Tony Kingsley has moved to The Medicines Company to take up the role of chief operating officer, where he will help oversee the New Jersey firm's day-to-day operations and lead its commercial activities.

He will also serve at the company, which focuses on serious infectious disease care, acute cardiovascular care, and surgery and perioperative care, as its president, taking over from Glenn Sblendorio, who retired in January.

Clive Meanwell, chief executive officer of The Medicines Company, said: “Tony brings extensive leadership experience and broad operational expertise developed over a long and enormously successful career. 

“His contributions will be invaluable as the company enters this exciting period and we continue to execute on our strategy to drive growth from our core, high-value assets, while maximising strategic and operational flexibility.”

Kingsley previously served as Biogen's executive vice president, global commercial operations, where the product launches he oversaw included the multiple sclerosis blockbuster Tecfidera (dimethyl fumerate).

Prior to that he spent time at Hologic as general manager of its gynaecological surgical products business and at Cytyc Corporation as president of its diagnostic products division.

Kingsley also previously worked as a partner at McKinsey & Company focusing on the biotechnology, pharmaceutical and medical device industries.

He said: “This is an extraordinary opportunity to be part of a company that carries the promise of profoundly improving and extending the lives of so many, while fundamentally altering the competitive landscape.”

26th May 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics